Alpa Laboratories Ltd

ALPA

Watchlist

AI Mode

‌

Market Cap

₹ 170 Cr

P/E

9.11

Turned 1 L into 2.20 L in last 5 Years

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

UNDERVALUED

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Alpa Laboratories Limited is a pharmaceutical company established in 1988, specializing in the manufacture of pharmaceutical formulations across various dosage forms, including injectables, tablets, and creams.

The company serves a broad market, including ethical, generic, over-the-counter drugs, and veterinary products, with a marked presence in both domestic and international markets.

Alpa Laboratories holds a robust contract manufacturing portfolio, servicing renowned pharmaceutical companies like Cipla, Zydus Cadila, and international markets in countries such as the Philippines and Nigeria.

The company underwent significant expansions, such as the establishment of a new manufacturing unit in 1999 and the operational start of their oral dosage facility in 2012.

In 2007, Alpa Laboratories went public, listing on major Indian stock exchanges and further expanding its market reach and capital base.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

170 Cr

Volatility

Moderate Risk

P/E Ratio

9.1

Industry P/E

30.5

PEG Ratio

0.8

P/B Ratio

0.9

52W High

137.40

52W Low

76.25

Sales CAGR

3.41%

0.06%

5.52%

10Y

7.75%

Profit CAGR

16.21%

11.69%

37.00%

10Y

10.93%

ROE

TTM

10.18%

10.67%

10.21%

10Y

7.27%

ROCE

TTM

12.57%

13.48%

13.39%

10Y

10.48%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AMBASARABH	29.09	222 Cr	14.20	1.50	0.00	10.60	10.22	3.70
SYSCHEM	48.55	211 Cr	46.73	2.23	0.00	4.78	5.68	2.49
NATCAPSUQ	186.00	196 Cr	—	0.87	0.00	-4.87	-1.11	-2.84
ALPA	80.08	170 Cr	9.11	0.93	0.00	10.18	12.57	7.85
BALAXI	29.04	166 Cr	11.43	0.70	0.00	6.09	7.48	4.50
SOTAC	123.40	136 Cr	17.76	2.56	0.00	15.37	16.39	8.19
ACHYUT	5.60	134 Cr	284.50	4.28	0.00	1.36	1.73	1.26

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	25	32	27	24	21	25	26	40	19	26
Expenses	27	29	25	20	21	22	25	40	19	29
Operating Profit	-1.14	3.35	2.43	3.51	0.52	3.32	0.74	0.20	0.42	-2.24
OPM %	-4.48	10.34	8.90	14.87	2.43	13.31	2.83	0.50	2.20	-8.53
Other Income	4.47	2.95	3.55	3.99	5.16	6.91	8.80	2.48	12	3.06
Interest	0.02	0.02	0.02	0.29	0.05	0.05	0.09	0.02	0.05	0.03
Depreciation	0.28	0.49	0.66	0.52	0.54	0.53	0.55	0.58	0.55	0.67
Profit Before Tax	3.03	5.79	5.30	6.67	5.10	9.65	8.90	2.08	12	0.11
Tax %	0.00	0.00	14.91	46.78	0.00	20.31	0.00	201.92	0.00	0.00
Net Profit	3.03	5.79	4.51	3.55	5.10	7.69	8.90	-2.12	12	0.11
EPS in Rs	1.44	2.75	2.17	1.71	2.42	3.66	4.23	-0.95	5.59	0.05

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	63	63	78	86	98	112	93	109	112	110
Expenses	56	59	77	83	90	102	85	101	108	105
Operating Profit	7.11	3.93	1.14	3.36	7.70	11	8.07	8.11	4.75	4.68
OPM %	11.20	6.25	1.47	3.90	7.89	9.50	8.69	7.45	4.23	4.25
Other Income	3.02	4.86	5.30	2.91	4.40	11	9.37	15	23	30
Interest	1.71	1.07	0.57	0.20	0.08	0.22	0.22	0.36	0.23	0.21
Depreciation	2.78	3.07	3.12	3.16	1.23	1.66	1.33	1.95	2.20	2.21
Profit Before Tax	5.64	4.64	2.76	2.91	11	20	16	21	26	32
Tax %	55.31	39.51	63.29	36.25	32.81	27.96	20.81	18.88	24.01	19.01
Net Profit	2.52	2.81	1.01	1.85	7.25	14	13	17	20	26
EPS in Rs	—	—	—	0.90	3.46	6.65	5.94	8.07	9.36	8.92
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	21	21	21	21	21	21	21	21	21	21
Reserves	72	74	77	77	79	87	101	114	131	150
Borrowings	24	11	5.79	1.46	0.19	0.19	5.85	2.30	5.25	0.03
Other Liabilities	27	20	18	21	21	33	28	30	25	51
Total Liabilities	144	126	122	121	121	140	155	167	182	223
Fixed Assets	15	11	10	7.78	6.41	7.21	9.32	7.04	11	21
CWIP	0.00	0.00	0.00	0.12	0.81	1.58	0.00	0.00	0.00	0.00
Investments	12	17	31	49	57	51	75	78	98	118
Other Assets	117	97	81	65	58	81	71	82	73	84
Total Assets	144	126	122	121	121	140	155	167	182	223

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-22	17	-13	-1.01	18	-1.71	9.94	8.90	3.65	18
Cash from Investing Activity	-8.03	-1.71	-11	-15	-11	5.86	-16	2.13	-13	-12
Cash from Financing Activity	-5.62	-15	8.83	-4.78	-1.35	0.19	5.44	-3.79	2.58	-5.44
Net Cash Flow	-35	0.05	-15	-20	5.27	4.34	-0.23	7.24	-7.10	0.51

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%	57.29%
FIIs	0.00%	0.00%	0.00%	0.11%	0.95%	0.50%	0.36%	0.74%	0.35%	0.40%	0.36%	0.35%
DIIs	0.00%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.00%	0.00%
Public	42.71%	42.69%	42.69%	42.60%	41.75%	42.20%	42.35%	41.96%	42.35%	42.31%	42.34%	42.35%
Total Shareholders	19,094	19,137	18,745	18,565	18,682	18,690	18,116	18,885	19,206	18,872	18,851	18,542

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Jun 26, 2025	Shitul shah	Insider - Promoter & Director	Acquisition	—	—	11,00,580	5.56
Jun 26, 2025	Pravin shah	Insider - Promoter & Director	Disposal	—	—	11,00,580	4.91
Jun 19, 2025	Pravin shah	Insider - Promoter & Director	Disposal	—	—	1,09,000	0.51
Jun 19, 2025	Shitul shah	Insider - Promoter & Director	Acquisition	—	—	1,09,000	0.51
Jun 18, 2025	Asha chawla	Insider - Promoter	Disposal	—	—	6,16,000	2.92
Jun 18, 2025	Mahendra singh chawla	Insider - Promoter & Director	Disposal	—	—	29,05,760	13.8
Jun 18, 2025	Paresh chawla	Insider - Promoter & Director	Acquisition	—	—	35,21,760	16.7
Sep 30, 2024	Qe securities llp	Bulk	Sell	139.75	2.81 Cr	2,00,761	0.95
Sep 30, 2024	Hrti private limited	Bulk	Buy	139.42	2.17 Cr	1,55,746	0.74
Sep 30, 2024	Qe securities llp	Bulk	Buy	139.76	2.85 Cr	2,03,805	0.96

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

The company serves a broad market, including ethical, generic, over-the-counter drugs, and veterinary products, with a marked presence in both domestic and international markets.

The company underwent significant expansions, such as the establishment of a new manufacturing unit in 1999 and the operational start of their oral dosage facility in 2012.

In 2007, Alpa Laboratories went public, listing on major Indian stock exchanges and further expanding its market reach and capital base.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln M/S

Market Cap

170 Cr

Volatility

Moderate Risk

P/E Ratio

9.1

Industry P/E

30.5

PEG Ratio

0.8

P/B Ratio

0.9

52W High

137.40

52W Low

76.25

Sales CAGR

3.41%

0.06%

5.52%

10Y

7.75%

Profit CAGR

16.21%

11.69%

37.00%

10Y

10.93%

ROE

TTM

10.18%

10.67%

10.21%

10Y

7.27%

ROCE

TTM

12.57%

13.48%

13.39%

10Y

10.48%